PMC:7796052 / 12392-13095 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"330","span":{"begin":158,"end":162},"obj":"Gene"},{"id":"331","span":{"begin":163,"end":168},"obj":"Gene"},{"id":"332","span":{"begin":266,"end":275},"obj":"Species"},{"id":"333","span":{"begin":363,"end":374},"obj":"Species"},{"id":"334","span":{"begin":670,"end":678},"obj":"Species"},{"id":"335","span":{"begin":74,"end":84},"obj":"Chemical"},{"id":"336","span":{"begin":243,"end":253},"obj":"Chemical"},{"id":"337","span":{"begin":457,"end":467},"obj":"Chemical"},{"id":"338","span":{"begin":647,"end":657},"obj":"Chemical"},{"id":"339","span":{"begin":106,"end":114},"obj":"Disease"},{"id":"340","span":{"begin":571,"end":579},"obj":"Disease"},{"id":"341","span":{"begin":661,"end":669},"obj":"Disease"}],"attributes":[{"id":"A330","pred":"tao:has_database_id","subj":"330","obj":"Gene:3569"},{"id":"A331","pred":"tao:has_database_id","subj":"331","obj":"Gene:6774"},{"id":"A332","pred":"tao:has_database_id","subj":"332","obj":"Tax:2697049"},{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"Tax:205488"},{"id":"A334","pred":"tao:has_database_id","subj":"334","obj":"Tax:9606"},{"id":"A335","pred":"tao:has_database_id","subj":"335","obj":"MESH:D020849"},{"id":"A339","pred":"tao:has_database_id","subj":"339","obj":"MESH:C000657245"},{"id":"A340","pred":"tao:has_database_id","subj":"340","obj":"MESH:C000657245"},{"id":"A341","pred":"tao:has_database_id","subj":"341","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The results of this work complement recent comments suggesting the use of raloxifene for the treatment of Covid-19 [45], based on its capacity to inhibit the IL-6/STAT3 signaling pathway [46,47]. In addition, the presumed antiviral profile of ralixofene against the SARS-Cov2 virus through its capability to block the two-pore channel TCP2 [48], as found for the ebola virus [49] has been underlined. In conclusion, the pharmacodynamic profile exhibited by ralidoxene described in the present report represents a reasonable base to test the compound for the treatment of Covid-19. Very recently a clinical trial in Italy has been approved to test ralixofene in COVID-19 patients with mild symptoms [50]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T79","span":{"begin":0,"end":195},"obj":"Sentence"},{"id":"T80","span":{"begin":196,"end":400},"obj":"Sentence"},{"id":"T81","span":{"begin":401,"end":580},"obj":"Sentence"},{"id":"T82","span":{"begin":581,"end":703},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The results of this work complement recent comments suggesting the use of raloxifene for the treatment of Covid-19 [45], based on its capacity to inhibit the IL-6/STAT3 signaling pathway [46,47]. In addition, the presumed antiviral profile of ralixofene against the SARS-Cov2 virus through its capability to block the two-pore channel TCP2 [48], as found for the ebola virus [49] has been underlined. In conclusion, the pharmacodynamic profile exhibited by ralidoxene described in the present report represents a reasonable base to test the compound for the treatment of Covid-19. Very recently a clinical trial in Italy has been approved to test ralixofene in COVID-19 patients with mild symptoms [50]."}